Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Procrit

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BACKGROUND Polycythemia vera is defined as a chronic myeloproliferative disorder characterized by increased red blood cell count… Expand
  • figure 1
  • figure 2
2013
2013
BACKGROUND: Polycythemia vera is defined as a chronic myeloproliferative disorder characterized by increased red blood cell count… Expand
  • figure 1
  • figure 2
Highly Cited
2008
Highly Cited
2008
Background: Craniosynostotic correction typically performed around infant physiologic nadir of hemoglobin (approximately 3-6… Expand
2007
2007
  • 2007
  • Corpus ID: 1589726
NEW DRUGS Lapatinib (Tykerb) For Advanced Breast Cancer The Food and Drug Administration (FDA) has approved lapatinib (Tykerb… Expand
2007
2007
PCN34 ANALYSIS OF DOSE, COST AND USE PATTERNS OF ERYTHROPOIETIN STIMULATING AGENTS IN CANCER PATIENTS Daniel GW, Hurley D,Whyte J… Expand
2003
2003
  • FDA consumer
  • 2003
  • Corpus ID: 35825285
 
2003
2003
  • AIDS treatment news
  • 2003
  • Corpus ID: 27668678
The FDA and Ortho Biotech have warned health professionals and patients to check for counterfeit Procrit, which may contain… Expand
2003
2003
W hen choosing which of two erythropoietic agents to prescribe for patients with chemotherapy-induced anemia, today’s clinicians… Expand
Highly Cited
1998
Highly Cited
1998
PURPOSE To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based… Expand
Highly Cited
1997
Highly Cited
1997
PURPOSE To study the impact of Procrit (epoetin alfa; Amgen Inc, Thousand Oaks, CA) on quality of life, transfusion requirements… Expand